
|Articles|October 12, 2019
Prescriber's Guide to Lasmiditan
In October 2019, the FDA approved Eli Lilly's lasmiditan, marketed as Reyvow, for the acute treatment of migraine with or without aura in adults. The drug is the first approved from a new class of serotonin (5-HT)1F receptor agonists. This downloadable PDF serves as a convenient, consolidated prescribing guide to help you incorporate this new migraine therapy into your clinical practice.
Advertisement
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
NeurologyLive® Brain Games: January 18, 2025
2
Investigational COYA 302 Shows Feasibility, Preliminary Efficacy in Small Trial of Frontotemporal Dementia
3
Efficacy and Safety Data for Tavapadon as an Emerging Therapy in Parkinson’s Disease
4
Efgartigimod Application Submitted for Seronegative gMG, EC Approves High-Dose Nusinersen, Copper Histidinate Gains First Approval for Menkes Disease
5



























